(CAMBRIDGE, Mass.)Biogen Idec Inc.'s third-quarter profit surged 73 percent on higher sales of the multiple sclerosis drugs Avonex and Tysabri, topping Wall Street forecasts and prompting the compan...READ MORE

(NEW YORK)Drug developer Biogen Idec Inc. reports earnings for the third quarter on Tuesday. The following is a summary of key developments and analyst opinion related to the period.READ MORE

(NEW YORK)Shares of Biogen Idec Inc. gained ground Friday after separate studies showed the positive long-term effects of the multiple sclerosis drug Avonex and allayed some side-effect fear...READ MORE

(NEW YORK)Biogen Idec Inc. said Friday its multiple sclerosis drug Tysabri may actually prompt an improvement in patients rather than simply halt the disease's progression, according to a re...READ MORE

(WASHINGTON)Best-selling drugs from Biogen Idec, Eli Lilly and GlaxoSmithKline are among those under investigation by federal regulators, who have released a first-ever list of ongoing safety ...READ MORE

(NEW YORK)Biogen Idec Inc. and Elan Corp. PLC said they have started the first clinical trial of their multiple sclerosis and Crohn's disease drug Tysabri as a treatment for cancer.READ MORE

(NEW YORK)Shares of Alkermes Inc. declined Wednesday as investors weighed potential bad news for one drug Alkermes helped develop with good news for another. Alkermes helped develop the long...READ MORE